Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Neuromyelitis Optica 1Myasthenia Gravis 1Hemoglobinuria, Paroxysmal 1Atypical Hemolytic Uremic Syndrome 1

Interventions

Cyclophosphamide 11fludarabine phosphate 8fludarabine 8apixaban 8Mycophenolic Acid 6Melphalan 6Busulfan 6Whole-Body Irradiation 4Tacrolimus 4Rivaroxaban 4Filgrastim 4Biopsy 4thymoglobulin 3X-Rays 3Specimen Handling 3Rituximab 3Peripheral Blood Stem Cell Transplantation 3Hematopoietic Stem Cell Transplantation 3Granulocyte Colony-Stimulating Factor 3Enoxaparin 3Bone Marrow Transplantation 3Azacitidine 3venetoclax 2pegylated granulocyte colony-stimulating factor 2olaparib 2Tretinoin 2Stem Cell Transplantation 2Mesna 2Injections 2Heparin, Low-Molecular-Weight 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × ravulizumab × Classical hematology × Clear all
NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔